Polyethylene Glycol

Summary

Polyethylene Glycol (CHEMBL1201478) is a phase-3 clinical-stage small molecule (ATC A06AD15); indicated across 17 conditions including constipation disorder and kawasaki disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A06AD15 (+1 more)
• Indications: 17 conditions
• Clinical trials: 83

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201478
Name	Polyethylene Glycol
Type	Small molecule
Max phase	3
ATC	A06AD15, A06AD65

Also known as: E-1521, E1521, INS NO.1521, INS-1521, Macrogol, Polyethylene glycol, unspecified, Polyethylene glycols, Polyethylene oxide, POLYETHYLENE GLYCOL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

17 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
constipation disorder	4	MONDO:0002203	HP:0002019
Kawasaki disease	3	MONDO:0012727	EFO:0004246
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182
anemia	3	MONDO:0002280	EFO:0004272
colonic neoplasm	3	MONDO:0005401	MONDO:0021063
radiodermatitis	2	MONDO:0043771	MONDO:0043771
dry eye syndrome	2	MONDO:0006733	EFO:1000906
irritable bowel syndrome	1	MONDO:0005052	EFO:0000555
obesity disorder	1	MONDO:0011122	EFO:0001073
Klebsiella infectious disease	1	MONDO:0030603	EFO:1001353
injury	1	MONDO:0021178	EFO:0000546
Parkinson disease	1	MONDO:0005180	MONDO:0005180
sarcoma	0	MONDO:0005089	EFO:0000691

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 83.

Phase distribution

Phase	Trials
PHASE4	31
Not specified	27
PHASE3	17
PHASE2	3
PHASE1	2
PHASE2/PHASE3	1
PHASE1/PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06455813	PHASE4	RECRUITING	What Laxative Should be Used After Hip Fracture Surgery?
NCT00493662	PHASE4	COMPLETED	Cross-Over Evaluation of Two Lubricating Eye Drops
NCT00603681	PHASE4	COMPLETED	Comparison of PEG Solutions With and Without Electrolytes in the Treatment of Constipation
NCT00677794	PHASE4	COMPLETED	Small Bowel Cleansing Prior to Video Capsule Endoscopy Examination
NCT01140295	PHASE4	TERMINATED	Bowel Preparation for Colonoscopy in Children
NCT01427296	PHASE4	COMPLETED	Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing
NCT01510977	PHASE4	TERMINATED	Second Bowel Preparation for Colonoscopy Failure
NCT01531140	PHASE4	COMPLETED	PEG Versus PEG+Bisacodyl Versus Sennosides for Colon Cleansing Before Colonoscopy
NCT01592734	PHASE4	COMPLETED	Efficacy and Tolerability of PEG-only Laxative for Fecal Impaction and Chronic Constipation in Children
NCT01711437	PHASE4	UNKNOWN	Different Bowel Preparations for Colonoscopy In Children
NCT01783782	PHASE4	UNKNOWN	Small Bowel Cleansing for Capsule Endoscopy in Pediatric Patients
NCT01810653	PHASE4	COMPLETED	A Study to Compare the Effect of Transipeg 2.95 g or Forlax Junior 4 g in Children With Constipation
NCT01887158	PHASE4	COMPLETED	Efficacy of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection
NCT02070341	PHASE4	TERMINATED	Patient Tolerability and Efficacy of Bowel Preparation With Split Dose Picosalax vs. Split Dose PEG
NCT02073552	PHASE4	COMPLETED	Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid.
NCT02396017	PHASE4	UNKNOWN	Split-dose Versus Single-dose Polyethylene Glycol Regimen for Capsule Endoscopy
NCT02419534	PHASE4	UNKNOWN	Pediatrics Anal Fissures Treatment With Polyethylene Glycol
NCT02486536	PHASE4	COMPLETED	The Best Dosage and Timing of Polyethylene Glycol for Bowel Preparation Before Capsule Endoscopy
NCT02507037	PHASE4	COMPLETED	Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy
NCT02956057	PHASE4	COMPLETED	Polyethylene Glycol Versus Low Volume Solutions Prior to Colonoscopy
NCT02977286	PHASE4	TERMINATED	Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids
NCT03100513	PHASE4	UNKNOWN	PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy
NCT03279341	PHASE4	COMPLETED	Effect of PEG, Bisacodyl and Prucalopride on Colonic Motility in Healthy Subjects
NCT03698474	PHASE4	COMPLETED	Comparison of Different Low Volume Solutions Prior to Colonoscopy
NCT03817788	PHASE4	COMPLETED	Randomized Controlled Trail of Polyethylene Glycol vs Sodium Phosphate for Colonic Cleansing of Colonoscopy
NCT03830489	PHASE4	COMPLETED	Impact of a Predictive Score of Bowel Preparation Quality in Clinical Practice
NCT04436601	PHASE4	UNKNOWN	Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Cirrhosis;(PEGHE Trial)
NCT04598880	PHASE4	COMPLETED	Comparison of 1 Liter PEG With Ascorbate and Sodium Picosulfate / Magnesium Citrate for High Quality Colon Cleansing
NCT04708366	PHASE4	UNKNOWN	Colon Cleansing Efficacy With 1L vs. 2L vs. 4L-PEG for Colonoscopy Among Inpatients
NCT05920213	PHASE4	UNKNOWN	Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy
NCT07605897	PHASE4	COMPLETED	Assessment of Safety, Quality, and Acceptance of a Bowel Preparation Using a Food Kit With Laxatives
NCT00403819	PHASE3	COMPLETED	Study to Examine the Efficacy and Safety of Movicol in the Treatment of Chronic Constipation in Children
NCT00403897	PHASE3	COMPLETED	An Open Single Centre Study To Assess Treatment of Chronic Constipation in Children
NCT00427089	PHASE3	COMPLETED	Comparison of 2L NRL994 With NaP Preparation in Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening
NCT00503607	PHASE3	COMPLETED	BLI-800-301: BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
NCT00503815	PHASE3	COMPLETED	BLI-800-302: BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
NCT00756548	PHASE3	COMPLETED	BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
NCT00756977	PHASE3	COMPLETED	BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
NCT00856843	PHASE3	COMPLETED	BLI800-303: An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects
NCT01229800	PHASE3	COMPLETED	Efficacy, Safety and Tolerability of Split-dose of PEG Compared With NaP Solution for Colonoscopy Preparation: A Randomized, Controlled Trial

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).